

## ■ NIH PATHWAY TO INDEPENDENCE AWARD (PARENT K99/R00): PA-15-083

### Components of Participating Organizations

*National Institutes of Health*  
*National Center for Complementary and Alternative Medicine*  
*National Cancer Institute*  
*National Eye Institute*  
*National Human Genome Research Institute*  
*National Heart, Lung, and Blood Institute*  
*National Institute on Aging*  
*National Institute on Alcohol Abuse and Alcoholism*  
*National Institute of Allergy and Infectious Diseases*  
*National Institute of Arthritis and Musculoskeletal and Skin Diseases*  
*National Institute of Biomedical Imaging and Bioengineering*  
*Eunice Kennedy Shriver National Institute of Child Health and Human Development*  
*National Institute on Drug Abuse*  
*National Institute on Deafness and Other Communication Disorders*  
*National Institute of Dental and Craniofacial Research*  
*National Institute of Diabetes and Digestive and Kidney Diseases*  
*National Institute of Environmental Health Sciences*  
*National Institute of General Medical Sciences*  
*National Institute of Mental Health*  
*National Institute of Neurological Disorders and Stroke*  
*National Institute of Nursing Research*  
*National Library of Medicine*  
*Office of Behavioral and Social Science Research*  
*Office of Dietary Supplements*  
*Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs*

Application Receipt/Submission Date(s): Multiple receipt dates, see announcement.

### Funding Opportunity Purpose

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions, and to provide independent NIH research support during the transition that will help these individuals launch competitive, independent research careers. Prospective candidates are strongly encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts ([http://grants1.nih.gov/grants/guide/contacts/parent\\_K99\\_R00.html](http://grants1.nih.gov/grants/guide/contacts/parent_K99_R00.html)). See also Frequently Asked Questions ([http://grants.nih.gov/grants/new\\_investigators/QsandAs.htm](http://grants.nih.gov/grants/new_investigators/QsandAs.htm)).

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-083.html>.

## ■ NIA ACADEMIC LEADERSHIP CAREER AWARD (K07): PAR-15-078

### Components of Participating Organizations

*National Institute on Aging*

Application Receipt/Submission Date(s): Multiple dates, see announcement.

### Funding Opportunity Purpose

The objective of the NIA Research Leadership Career Award (K07) is to provide support for more senior investigators who have the

expertise and leadership skills to enhance the aging and geriatric research capacity within their academic institution.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-078.html>.

## ■ CUTTING-EDGE BASIC RESEARCH AWARDS (CEBRA) (R21): PAR-15-079

### Components of Participating Organizations

*National Institute on Drug Abuse*

Application Receipt/Submission Date(s): August 20, 2015; December 18, 2015; August 19, 2016; December 20, 2016; August 18, 2017; and December 20, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

### Funding Opportunity Purpose

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to drug abuse and addiction and how to prevent and treat them. It supports research that is high-risk and potentially high-impact that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test a highly novel and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking; and/or (2) develop or adapt innovative techniques or methods for addiction research, or that have promising future applicability to drug abuse research.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-079.html>.

## ■ NIAMS RHEUMATIC DISEASES RESEARCH RESOURCE-BASED CENTERS (P30): RFA-AR-16-002

### Components of Participating Organizations

*National Institute of Arthritis and Musculoskeletal and Skin Diseases*

Application Receipt Date(s): October 09, 2015

### Funding Opportunity Purpose

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for rheumatic diseases research areas within its mission. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on rheumatic diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.

Complete details available at: <http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-16-002.html>.

## ■ NIGMS PROGRAM OF ADMINISTRATIVE SUPPLEMENTS FOR EQUIPMENT (ADMIN SUPP): PA-15-089

### Components of Participating Organizations

*National Institute of General Medical Sciences*

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**Funding Opportunity Purpose**

The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded R01, R37, P01, and U01 grants. These funds are intended for the purchase of single pieces of equipment whose requested direct costs are between \$50,000 and \$250,000. Equipment in this price range is often difficult to purchase under the parent grant. Two or more NIGMS grantees at the same institution with similar equipment needs are encouraged to submit separate requests (each between \$50,000 and \$250,000) that cross-reference each other. It is expected that the amount of funds requested for such joint purchases will reflect the actual proportion of the time that the shared equipment would be used by each PI. NIGMS encourages requests that reflect institutional commitment.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-089.html>.

■ **SHARED INSTRUMENTATION GRANT (SIG) PROGRAM (S10): PAR-15-088**

**Components of Participating Organizations**

*Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs*

Application Receipt/Submission Date(s): May 29, 2015

**Funding Opportunity Purpose**

The Shared Instrument Grant (SIG) program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems that cost at least \$50,000. The maximum award is \$600,000. Types of instruments supported include, but are not limited to: X-ray diffraction systems, nuclear magnetic resonance (NMR) and mass spectrometers, DNA and protein sequencers, biosensors, electron and confocal microscopes, cell-sorters, and biomedical imagers.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-088.html>.

■ **BRAIN INITIATIVE: DEVELOPMENT, OPTIMIZATION, AND VALIDATION OF NOVEL TOOLS AND TECHNOLOGIES FOR NEUROSCIENCE RESEARCH (STTR) (R41/R42): PAR-15-090**

**Components of Participating Organizations**

*National Institute of Mental Health  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
National Institute on Drug Abuse  
National Institute on Deafness and Other Communication Disorders*

*National Institute of Neurological Disorders and Stroke*

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**Funding Opportunity Purpose**

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research, including 1) tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function, 2) proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular

resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain, and 3) iterative refinement of such tools and technologies with the end-user community with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-090.html>.

■ **BRAIN INITIATIVE: DEVELOPMENT, OPTIMIZATION, AND VALIDATION OF NOVEL TOOLS AND TECHNOLOGIES FOR NEUROSCIENCE RESEARCH (SBIR) (R43/R44): PAR-15-091**

**Components of Participating Organizations**

*National Institute of Mental Health  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
National Institute of Biomedical Imaging and Bioengineering  
National Institute on Drug Abuse  
National Institute on Deafness and Other Communication Disorders*

*National Institute of Neurological Disorders and Stroke*

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**Funding Opportunity Purpose**

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research including 1) tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function, 2) proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain, and 3) iterative refinement of such tools and technologies with the end-user community with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-091.html>.

■ **EXPLORATORY/DEVELOPMENTAL GRANTS PROGRAM FOR BASIC CANCER RESEARCH IN CANCER HEALTH DISPARITIES (R21): PAR-15-092**

**Components of Participating Organizations**

*National Cancer Institute*

Application Receipt/Submission Date(s): June 17, 2015; November 17, 2015; June 17, 2016; November 17, 2016; June 19, 2017; November 17, 2017, by 5:00 PM local time of applicant organization.

**Funding Opportunity Purpose**

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities,

(2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PAR-15-092.html>.

## ■ BASIC CANCER RESEARCH IN CANCER HEALTH DISPARITIES (R01): PAR-15-093

### Components of Participating Organizations

*National Cancer Institute*

Application Receipt/Submission Date(s): June 17, 2015; November 17, 2015; June 17, 2016; November 17, 2016; June 19, 2017; November 17, 2017, by 5:00 PM local time of applicant organization.

#### *Funding Opportunity Purpose*

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention intervention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PAR-15-093.html>.

## ■ ASSAY VALIDATION FOR HIGH QUALITY MARKERS FOR NCI-SUPPORTED CLINICAL TRIALS (UH2/UH3): PAR-15-095

### Components of Participating Organizations

*National Cancer Institute*

Application Receipt/Submission Date(s): March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

#### *Funding Opportunity Purpose*

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. The UH2 phase of this FOA supports analytical validation of assays for these markers that must be achieved within two

years before an assay may undergo clinical validation. The UH3 phase of this FOA supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. In both the UH2 and UH3 phases, clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials. Investigators responding to this FOA must address both UH2 and UH3 phases.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PAR-15-095.html>.

## ■ ASSAY VALIDATION FOR HIGH QUALITY MARKERS FOR NCI-SUPPORTED CLINICAL TRIALS (UH3): PAR-15-096

### Components of Participating Organizations

*National Cancer Institute*

Application Receipt/Submission Date(s): March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

#### *Funding Opportunity Purpose*

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants to this FOA must have an assay whose performance has been analytically validated within specimens similar to those for the intended clinical use of the assay and marker. The UH3 mechanism supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PAR-15-096.html>.

## ■ NIAMS MUSCULOSKELETAL BIOLOGY AND MEDICINE RESOURCE-BASED CENTERS (P30): RFA-AR-16-004

### Components of Participating Organizations

*National Institute of Arthritis and Musculoskeletal and Skin Diseases*

Application Receipt Date(s): June 11, 2015

**Funding Opportunity Purpose**

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in musculoskeletal biology and medicine. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on musculoskeletal biology and medicine, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.

Complete details available at: <http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-16-004.html>.

■ **MAXIMIZING INVESTIGATORS' RESEARCH AWARD (R35): RFA-GM-16-002**

**Components of Participating Organizations**

*National Institute of General Medical Sciences*

Application Receipt Date(s): May 20, 2015

**Funding Opportunity Purpose**

The Maximizing Investigators' Research Award (MIRA) is a grant to provide support for all of the research in an investigator's laboratory that falls within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that the new program will:

- Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively.
- Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies.
- More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs.
- Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research.
- Enable principal investigators to devote more time and energy to mentoring junior scientists in a more stable research environment.

The purpose of this FOA is to test the feasibility of this grant mechanism through a pilot program with restricted eligibility.

Complete details available at: <http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-16-002.html>.

■ **MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01): PA-15-100**

**Components of Participating Organizations**

*National Institute of Nursing Research Office of Dietary Supplements*

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**Funding Opportunity Purpose**

This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intra-uterine environment, and subsequently fetal development and the health of the newborn.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-100.html>.

■ **CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01): PAR-15-104**

**Components of Participating Organizations**

*National Cancer Institute*

Application Receipt/Submission Date(s): April 1, 2015; July 8, 2015; November 10, 2015; March 11, 2016; July 8, 2016; November 10, 2016; March 10, 2017, by 5:00 PM local time of applicant organization.

**Funding Opportunity Purpose**

The Funding Opportunity Announcement (FOA) invites grant applications for targeted infrastructure support of the core functions of Cancer Epidemiology Cohorts (CECs) and methodological research. Through this FOA, the National Cancer Institute (NCI) will support infrastructure and core functions for existing or new CECs. This FOA will also lead to support of core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of the Division of Cancer Control and Population Sciences (DCCPS) at the NCI.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PA-15-104.html>.

■ **MULTILEVEL INTERVENTIONS IN CANCER CARE DELIVERY: BUILDING FROM THE PROBLEM OF FOLLOW-UP TO ABNORMAL SCREENING TESTS (U01): PAR-15-108**

**Components of Participating Organizations**

*National Cancer Institute*

Application Receipt/Submission Date(s): April 9, 2015; November 25, 2015; May 26, 2016; September 21, 2016; May 26, 2017; September 21, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Funding Opportunity Purpose**

This Funding Opportunity Announcement (FOA) encourages applications that strengthen the science of multilevel effects of cancer care interventions by addressing the problem of incomplete follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers. The goals of this FOA are two-fold. First, this FOA seeks to advance the science of multilevel interventions in three ways: a) by establishing a common conceptualization of levels and the associated level-specific factors that affect practice; b) by standardizing metrics of the levels and their main effects on other levels and the individuals needing

follow-up care; and c) by developing and standardizing the analysis of the effect of interventions on the individuals, groups, and organizations responsible for intervention implementation. Second, this FOA encourages applications that test interventions to improve the follow-up of abnormal screening in one or more

ways, including: a) measuring multilevel effects of single-level interventions; b) comparing single vs. multilevel interventions; and c) testing multilevel interventions.

Complete details available at: <http://grants.nih.gov/grants/guide/pa-files/PAR-15-108.html>.